70-year-old-woman with extremely dense breasts

70-year-old-woman with extremely dense breasts. A. Axial subtracted contrast-enhanced fat-suppressed T1-weighted image from baseline AB-MR examination is negative (BI-RADS category 1). B. Axial subtracted contrast-enhanced fat-suppressed T1-weighted image from subsequent-round AB-MR examination performed 2 years later shows new 5-mm enhancing mass in upper outer right breast (arrow), which was not seen on mammogram performed 5 months prior. Examination was assessed as BI-RADS category 5. Ultrasound-guided core biopsy yielded invasive ductal carcinoma (ER+/PR+/HER2-).


June 6, 2024 — Subsequent rounds of abbreviated breast MRI (AB-MR) screening in patients with dense breasts had lower abnormal interpretation rate (AIR) compared to baseline examinations, while maintaining high cancer detection rate (CDR), according to the American Journal of Roentgenology (AJR).

Pointing out that all cancers detected by subsequent-round examinations were early-stage node-negative cancers, “further investigations are warranted to optimize the screening interval,” noted first author Christine E. Edmonds, MD, from the Hospital of the University of Pennsylvania. “The findings support sequential AB-MR for supplemental screening in individuals with dense breasts.”

AJR Editor in Chief Andrew Rosenkrantz, MD, speaks with Dr. Edmonds about her study comparing outcomes between baseline and subsequent rounds of screening abbreviated breast MRI in individuals with dense breasts.

Edmonds et al.’s AJR accepted manuscript included patients with dense breasts, at otherwise average breast-cancer risk, who underwent AB-MR for supplemental screening between December 20, 2016 and May 10, 2023. After extracting clinical interpretations and results of recommended biopsies for AB-MR examinations from the EMR, the researchers compared baseline and subsequent-round AB-MR examinations.

Ultimately, in women with dense breasts, subsequent-round AB-MR for supplemental screening achieved lower AIR versus baseline rounds (7.8% vs. 17.4%, p <.001), while maintaining high CDR (12.1 vs. 18.9 per 1000, p =.37). All cancers diagnosed by subsequent round AB-MR were stage 0 or 1; had size of 0.3-1.2 cm; and exhibited node-negative status.

For more information: www.arrs.org


Related Content

News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Breast Imaging

Jan. 027, 2026 — QT Imaging and Olea Medical have announced plans to collaborate. This collaboration enhances QT Imaging ...

Time January 27, 2026
arrow
News | Mammography

Jan. 16, 2026 — Vega Imaging Informatics has announced the successful curation of the world’s largest digital breast ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — VizMark has received U.S. Food and Drug Administration FDA 510k clearance for VM1, a non-metal visual ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — Susan G. Komen, the world’s leading breast cancer organization commends Assemblymember Lori Wilson (D ...

Time January 16, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — iSono Health has announced the commercial launch of ATUSA, an FDA-cleared, wearable and automated 3D ...

Time January 14, 2026
arrow
News | Women's Health

Dec. 12. 2025 — A new study has found that an individualized approach to breast cancer screening that assesses patients’ ...

Time December 17, 2025
arrow
News | Breast Imaging

Dec. 16, 2025 — Hologic, Inc, a medical technology company dedicated to improving women’s health, recently announced new ...

Time December 16, 2025
arrow
Subscribe Now